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Background: The physiological functions of the classical HLA (human leukocyte
antigen) molecules, HLA-A, HLA-B and HLA-C, are to present peptides to T cells
and to inhibit the activity of natural killer cells. In contrast, the functions of
nonclassical HLA-molecules, such as HLA-E, HLA-F and HLA-G, remain to be
established. The expression of HLA-G is largely limited to the placental
trophoblast, where it might mediate protection of the fetus from rejection by the
mother. Achieving the aim of understanding the function of HLA-G should be
facilitated by information on the biochemical properties of HLA-G molecules,
especially on their potential ability to act as peptide receptors.
Results: To study peptide presentation by HLA-G, we used stably transfected
LCL721.221 cells as a source of HLA-G molecules and analysed the spectrum
of extracted peptides by individual and pool sequencing. Our results indicate
that HLA-G molecules, like classical HLA molecules, are associated with a wide
array of peptides derived from cellular proteins. Peptides presented by HLA-G
usually consisted of 9 amino acids, and adhered to a specific sequence motif,
with anchor residues at position 2 (isoleucine or leucine), position 3 (proline) and
the carboxy-terminal position 9 (leucine). Thus, the HLA-G peptide ligand motif
follows the principles of classical HLA motifs, although it displays its own unique
features. Peptide-binding assays indicated that two of the three anchor residues
were sufficient for binding, and that the three natural HLA-G ligands that we
identified bound, not only to HLA-G, but also to HLA-A2. This was not surprising,
because the binding pockets of HLA-A2 and HLA-G overlap in their ability to
recognize anchor residues at positions 2 and 9. Likewise, some, but not all, HLA-
A2 peptide ligands could also bind to HLA-G.
Conclusions: Nonclassical HLA-G molecules present peptides essentially in the
same way as classical HLA molecules do. We determined the peptide motif that
is specifically recognized by HLA-G; its basic features are described by the
sequence XI/LPXXXXXL. This information should help to elucidate the
physiological role of HLA-G molecules at the fetal–maternal interface. Most likely,
this role is to protect fetal cells from lysis by natural killer cells, and possibly to
present foreign peptides to a class of T cells that has not yet been identified.
Background
The classical genes of the human class I major histocompat-
ibility complex (MHC) — the human leukocyte antigen
(HLA)-A, HLA-B and HLA-C genes — had been known
about for a long time when molecular biology techniques
led to the discovery of the nonclassical HLA genes
(reviewed in [1]). Although the function of the classical
HLA molecules as polymorphic peptide receptors is well
documented (reviewed in [2,3]), the function of the non-
classical HLA molecules remains to be established. In the
mouse, some of the nonclassical MHC molecules display
specialized antigen-presentation functions; for example,
some present antigenic peptides containing an N-formyl
group and others present lipid antigens (reviewed in [4]).
By analogy, specialized functions have been suggested for
the nonclassical HLA proteins [5], although there is no
homology between these molecules and the nonclassical
mouse MHC proteins [1]. Of the nineteen nonclassical
HLA sequences known to date, three — HLA-E, HLA-F
and HLA-G — are expressed (reviewed in [6]). The almost
monomorphic HLA-G was found to be expressed in the tro-
phoblast of human placenta [7,8], predominantly at the
fetal–maternal interface along the invasive pathway. There,
HLA-G can mainly be found on the extravillous cytotro-
phoblast and the amnion [9–12] (Fig. 1). Apart from this
extraordinary tissue distribution, the existence of five dif-
ferentially spliced HLA-G mRNAs, lacking none, one, or
two exons of the genomic HLA-G sequence, is remarkable
[13,14]. In addition, the largest mRNA, which encodes all of
the a domains (a1, a2 and a3), gives rise to five isoforms of
the HLA-G a chain [15]. All but one of the HLA-G mRNA
products seem to stay at the cell surface, whereas the
Addresses: *Abteilung Tumorvirus-Immunologie
(0620), Deutsches Krebsforschungszentrum, 
Im Neuenheimer Feld 242, 69120 Heidelberg,
Germany. †Division of Immunology, Department of
Pathology, University of Cambridge, Tennis Court
Road, Cambridge, CB2 1QP, UK. ‡Research
Group in Human Reproductive Immunobiology,
Department of Pathology, University of Cambridge,
Tennis Court Road, Cambridge, CB2 1QP, UK.
Correspondence to: H-G. Rammensee.
Received: 17 November 1995
Revised: 19 January 1996
Accepted: 29 January 1996
Current Biology 1996, Vol 6 No 3:305–314
© Current Biology Ltd ISSN 0960-9822
Research Paper 305
37 kDa HLA-G a chain seems to form a soluble MHC class
I molecule [16]. The expression of HLA-G at the
fetal–maternal interface has led to the suggestion that it
plays a role in maternal tolerance against the fetal semiallo-
graft. Three mechanisms for this tolerance have been sug-
gested: first, the presence of HLA-G on the cell surface
might prevent lysis by decidual CD56+ natural killer (NK)
cells [17,18]; second, gd T cells, which make up 6–9 % [19],
or even 27 % [20], of the CD3+ T cell population in the
decidua during early pregnancy, may be induced by HLA-
G to suppress rejection of the semiallograft by CD8+ cyto-
toxic T cells; and finally, soluble HLA-G might have some
suppressive effect on T cells.
Apart from these putative specific functions for HLA-G,
parallels to classical HLA molecules have been found.
Firstly, an interaction between HLA-G and CD8 has been
described [21]. Secondly, in the tamarin Saguinus oedipus, an
ortholog of HLA-G serves as a restricting element [22,23].
Thirdly, limited polymorphism of HLA-G was detected in
Afro–Americans [24]. Finally, indirect evidence for peptide
loading by HLA-G was provided by the finding that the
expression of TAP, the transporter associated with antigen
presentation, parallels HLA-G expression in the human tro-
phoblast [25,26]. We therefore investigated the capacity of
HLA-G molecules to present peptides. Here we report the
isolation of HLA-G peptide ligands from transfected cell
lines and their characterization by sequencing, mass spec-
trometry and peptide-binding studies.
Results
Isolation of HLA-G associated peptides
As a source of HLA-G, we used the HLA-null lympho-
blastoid cell line LCL721.221 transfected with a plasmid
encoding the HLA-G gene [17,27,28]. Transfectants were
grown in liquid roller bottle cultures to 1010 cells and more.
HLA-G molecules were isolated from cell pellets by deter-
gent extraction followed by immunoprecipitation with the
solid-phase-bound antibody W6/32 [29], which is specific
for a monomorphic determinant on HLA-molecules. Pep-
tides associated with HLA-G were extracted from the
HLA–antibody complexes by treatment with trifluoroacetic
acid (TFA), as described for other MHC molecules [30],
and separated by reversed-phase high-performance liquid
chromatography (HPLC) (Fig. 2). In order to control for
material sticking nonspecifically to the solid phase, the cell
lysate was also mock-precipitated with beads coupled to
glycine instead of antibodies. Material extracted from the
mock-precipitate was also separated by HPLC (Fig. 2,
dashed line). The HPLC profile clearly indicates that a
considerable amount of heterogeneous material, most prob-
ably a complex mixture of peptides, had been specifically
recovered from HLA-G molecules. As a further control,
non-transfected LCL721.221 cells were detergent-
extracted and immunoprecipitated with W6/32 antibodies.
TFA extraction and HPLC separation of this material did
not yield any HPLC profile over background (data not
shown). In order to compare the peptides extracted from
classical HLA molecules, LCL721.221 cells were trans-
fected with a plasmid encoding HLA-A2.1 and subjected to
the same procedure. The HPLC profile of the peptides
eluted from HLA-A2.1 (data not shown) looked very similar
to those eluted from HLA-G. Thus, HLA-G and HLA-A2.1
both seem to be associated with a mixture of peptides.
Pool sequencing of HLA-G associated peptides
Pool sequencing of class I ligands is a fast and convenient
way to obtain the features, or motif, shared by all peptides
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Figure 1
A placental section showing the different
trophoblast populations. Villous
cytotrophoblast and villous syncytiotropho-
blast are both HLA-G negative. All the other
trophoblast populations are HLA-G positive.
Decidual NK cells are found in the decidua
basalis in close contact with interstitial
trophoblast cells. (Adapted from [41].)
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associated with a particular MHC class I molecule [30].
After setting aside several well separated peak fractions
for individual sequencing, all remaining fractions of the
HLA-G extracted material, corresponding to elution times
of 40–55 minutes, were combined and subjected to pool
sequencing. This was performed in a total of four inde-
pendent experiments. Table 1 shows the raw data of two
of these.
The most striking feature of the pool sequencing patterns
(Table 1) is that the HLA-G ligands preferentially contain
hydrophobic residues at positions 2, 7 and 9, and a proline
residue at position 3. Position 2 is occupied by isoleucine
or leucine at a ratio of 2:1, position 7 is preferentially occu-
pied by isoleucine or valine (or, to a lesser extent, leucine
or phenylalanine). Position 9 represents the carboxyl ter-
minus of the ligands, as indicated by the absence of
signals in later positions and by the rapid, nonlinear
decrease of all amino acids. This position seems to be
exclusively occupied by leucine, but this anchor residue
was only visible in two out of four pool sequencing experi-
ments. The reason for this inconsistency is probably tech-
nical, because Edman degradation is difficult to perform at
carboxy-terminal sites of peptides. As in many HLA class
I ligand motifs, mostly hydrophilic residues are favoured
in the central region of the ligands, around positions 4 and
5. The pool sequencing experiments also revealed other
preferred amino acids: lysine or arginine at position 1,
tyrosine at position 6, and glutamine or methionine (or
sometimes lysine) at position 8. In addition, many weaker
signals for various amino acids at positions 4 through 8
were detected. Thus, these data clearly indicate that
HLA-G molecules are associated with a complex mixture
of peptides with a specific sequence pattern.
For comparison, the peptide mixture extracted from
LCL721.221-derived HLA-A2.1 molecules was also sub-
jected to pool sequencing. The result was consistent with
that found earlier for HLA-A2.1 ligands obtained from JY
cells [30] (data not shown). The comparison of pool
sequences for HLA-G and HLA-A2.1 ligands indicates
that peptides associated with HLA-G have a distinct
sequence motif, which overlaps with the peptide motif
recognized by HLA-A2.1.
Identification of individual HLA-G ligands
The prominent HPLC peak fractions that were excluded
from the pool were sequenced individually. We identified
three individual peptides: RIIPRHLQL, which was
derived from histone H2A, and RLPKDFRIL/KLPAQ-
FYIL, both of which were from unknown sources (Table
2). The mass of the histone-derived peptide was con-
firmed by mass spectrometry. All three peptides were 9
amino-acids long, had a leucine residue at position 9 and a
positively charged amino acid at the amino terminus.
Thus, the aliphatic residues at position 2 and 9 of all three
ligands confirmed the anchor residues determined by pool
sequencing. The proline anchor residue at position 3 was
also present in two of the three ligands; the remaining
peptide had its proline residue at position 4.
A clear-cut HLA-G ligand motif emerged when the pool
sequencing data and the sequences of the individual
ligands were combined (Table 2). HLA-G ligands con-
sisted of 9 amino acids, with the following anchor residues:
isoleucine or leucine at position 2, proline at position 3
and leucine at the carboxyl terminus. In addition, there
was a preference for a positively charged residue at posi-
tion 1, as confirmed for all three ligands, for an aromatic
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Figure 2
HPLC profile of the HLA-G ligand separation.
HPLC separations were carried out as
described [30]. The control trace represents
material non-specifically bound by glycine-
blocked sepharose.
residue at position 6, for leucine at position 7 and for glut-
amine at position 8, as indicated by pool sequencing. The
latter preferences are also reflected by the sequences of
individual ligands: the peptides KLPAQFYIL and RLP-
KDFRIL have an aromatic residue at position 6, and the
peptide RIIPRHLQL has a leucine residue at position 7
and a glutamine at position 8.
Peptide-binding studies. 
Incubation with binding peptides increases the cell-surface
density of at least some MHC molecules [31]. We therefore
tested whether this might also be the case with HLA-G on
LCL721.221 cells. Figure 3 shows that the density of HLA-
G on the cell-surface increased 2–3-fold upon incubation
with the HLA-G ligand RIIPRHLQL, as indicated by
FACS (fluorescence-activated cell sorting) analysis.
Although it was not expected, we found that the density
of HLA-A2 increased after incubating HLA-A2.1 express-
ing LCL721.221 cells with synthetic HLA-A2.1 ligands
(Fig. 3e,g). The HLA-G ligand RIIPRHLQL also bound
to HLA-A2.1 (Fig. 3c), and conversely, the HLA-A2.1
ligand ILKEPVHGV bound to HLA-G (Fig. 3d). This
overlap of binding specificities was not unexpected,
because the main features of the HLA-A2.1 peptide motif
— a length of 9 amino acids and aliphatic anchor residues
at positions 2 and 9 — were reproduced in the HLA-G
motif. The overlap was not complete, however, as illus-
trated by the HLA-A2.1 ligand YMNGTMSQV, which
bound to HLA-A2.1 but not to HLA-G (Fig. 3f,g). That
the peptide-binding assay used here was peptide-specific
was further demonstrated by the lack of binding of an
HLA-B27 ligand, GRLTKHTKF, to both HLA-G and
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Table 1
Pool sequencing of the ligand mixture eluted from HLA-G molecules.
Experiment 1
Amino-acid residues (in pmol)
Cycle Ala Arg Asn Asp Glu Gln Gly His Ile Leu Lys Met Phe Pro Ser Thr Trp Tyr Val
no. A R N D E Q G H I L K M F P S T W Y V
1 56.0 22.5 128.8 52.5 – 7.6 – – 13.7 2.6 69.3 7.9 11.0 9.1 47.9 – 5.0 12.1 30.8
2 29.7 10.4 46.6 25.3 – 4.4 – – 54.5 37.4 17.8 6.0 8.3 5.7 28.7 – 3.9 15.5 18.1
3 21.2 4.7 22.1 19.3 – 2.8 – – 41.4 5.0 8.2 0.9 2.1 70.6 11.4 – 5.3 5.3 15.9
4 28.8 3.3 14.8 19.6 – 2.5 – – 5.3 10.4 29.6 2.3 2.4 29.0 7.2 – 7.1 3.4 9.1
5 12.0 4.7 13.9 19.6 – 3.7 – – 4.8 15.8 23.5 2.4 4.1 11.6 8.0 – 7.0 5.4 11.5
6 14.0 5.5 10.8 12.8 – 2.1 – – 5.7 8.4 23.6 2.3 7.2 6.9 6.6 – 5.8 12.4 10.8
7 6.4 3.4 7.6 8.9 – 1.3 – – 24.7 12.3 7.6 1.4 7.1 3.9 6.2 – 4.0 5.0 23.8
8 5.8 3.6 5.0 7.2 – 4.0 – – 6.0 7.6 8.9 3.1 2.9 2.7 5.1 – 3.6 4.3 14.4
9 2.9 2.6 4.7 5.4 – 1.5 – – 3.0 15.4 3.7 1.6 1.6 2.2 5.6 – 3.7 1.6 5.1
10 1.8 2.0 4.2 3.5 – 0.7 – – 0.4 4.8 1.8 0.5 0.8 1.3 4.9 – 3.1 1.0 2.7
Experiment 2
Amino-acid residues (in pmol)
Cycle Ala Arg Asn Asp Glu Gln Gly His Ile Leu Lys Met Phe Pro Ser Thr Trp Tyr Val
no. A R N D E Q G H I L K M F P S T W Y V
1 24.7 91.2 6.4 4.1 13.7 3.9 56.5 7.9 13.5 8.8 45.2 26.4 7.8 8.4 16.1 – 0.4 9.0 36.8
2 23.0 44.9 4.3 4.1 15.6 12.5 70.3 1.3 135.8 59.4 15.9 15.6 13.3 13.3 13.0 – 0.2 8.9 40.8
3 34.8 24.5 5.6 9.8 17.3 6.8 65.3 2.6 106.5 13.4 8.9 5.0 4.5 105.8 7.4 – 0.3 5.1 35.6
4 44.3 31.3 10.8 21.0 28.4 9.5 51.6 2.0 21.9 15.9 50.4 6.6 5.4 74.4 7.6 – 0.2 8.6 20.9
5 28.8 57.8 9.8 37.1 41.8 15.4 56.3 5.2 9.7 23.6 52.9 5.3 7.1 34.4 10.8 – 0.6 8.4 26.5
6 36.1 65.8 10.3 33.0 34.1 12.6 49.3 9.0 7.1 19.3 56.9 4.2 7.6 21.5 9.2 – 0.2 23.7 17.5
7 23.8 71.8 8.6 29.3 25.2 9.6 40.2 9.6 35.9 38.6 34.6 6.2 11.8 17.3 6.3 – 0.4 13.5 46.9
8 15.9 79.3 8.5 24.0 30.2 19.5 35.9 7.5 21.3 30.5 36.4 9.7 8.0 12.5 4.9 – 0.3 9.6 35.2
9 12.2 83.1 7.7 21.4 29.8 17.8 33.5 6.1 14.8 29.2 23.1 9.2 9.1 12.9 4.6 – 0.2 7.2 22.0
10 10.8 45.6 6.2 12.0 20.1 11.9 30.3 3.5 6.0 19.3 10.6 9.1 3.5 9.1 3.5 – 0.1 5.6 11.7
11 9.2 57.9 6.6 12.0 17.4 12.2 27.1 2.3 5.1 12.6 8.7 4.8 4.7 8.3 3.5 – 0.4 4.9 8.1
12 6.5 54.8 5.2 12.4 10.2 8.4 25.2 1.8 3.2 8.6 7.7 2.8 3.6 7.8 3.0 – 0.3 5.3 5.9
HLA molecules were precipitated from transfected LCL721.221 cells
and the peptides extracted. Raw data of peptide pool sequencing are
shown [30]. Values showing > 50 % increase compared to the
previous (or pre-previous) cycle are defined as signals and are
underlined; values with > 100 % increase are referred to as strong
signals and are shown in bold [30]. In addition, positions following a
signal are defined as a signal of the same quality if the pmol amount of
the respective PTH-amino acid (the derivative detected in Edman
degradation) is constant or still increasing (for example, F6 in
experiment 1, or K6 and H7 in experiment 2). PTH-T coeluted with a
major contaminant and its values are therefore omitted from the table.
In the first experiment, PTH-E, PTE-G and PTE-H were hidden under
contaminant peaks, so they could not be evaluated.
HLA-A2.1. The other two HLA-G ligands, RLPKDFRIL
and KLPAQFYIL, also bound to both HLA-G and HLA-
A2.1 (data not shown), confirming the overlap of both
motifs.
Further peptide-binding studies confirmed the predicted
anchor positions of HLA-G peptide ligands. The amino
acids at positions 2, 3 and 9 of the peptide KIPAQFYIL (a
variant of the ligand KLPAQFYIL, designed to express
the best motif match at every anchor position) were sub-
stituted with glycine, and the original anchor residues
were successively reintroduced. KIPAQFYIL itself
strongly stabilized MHC class I density on LCL721.221.G
cells upon overnight incubation (Fig. 4a). However,
KGGAQFYIG had no stabilizing effect at all. We found
that stabilization could be achieved to some extent with
KGGAQFYIL, and that the stabilizing effect of KGPAQ-
FYIL was similar to that of KIPAQFYIL (Fig. 4b). There-
fore, the three anchor positions, 2, 3 and 9, as determined
by ligand analysis, were confirmed by peptide-binding
analysis; moreover, two out of the three anchor residues
were sufficient for reasonable binding.
Discussion
HLA-G molecules are peptide receptors. The peptide
specificity of HLA-G molecules is similar to that of classi-
cal MHC molecules [32]. HLA-G molecules present pep-
tides that are predominantly 9 residues in length, as
indicated by ligand sequencing. Histone H2A, identified
as the donor protein for one ligand, is also a common
ligand source for classical MHC molecules [3]. The
sequence criteria for peptides to be recognized by HLA-G
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Table 2
Comparison of HLA-G and HLA-A2 peptide motifs.
HLA-G Position
1 2 3 4 5 6 7 8 9
Anchor residues I P L
L
Preferred residues R Y I Q
K V M
L
F
Individual ligands *R I I P R H L Q L
†R L P K D F R I L
‡K L P A Q F Y I L
HLA-A2 Position
1 2 3 4 5 6 7 8 9
Anchor residues L V
M L
Preferred residues E V K
K
The technique of pool sequencing and the criteria for evaluating the
raw sequencing data are described in Table 1 and in [30]. Increases of
pmol values, compared to previous cycles, that were reproduced in
four independent experiments and/or the individual ligands were
judged significant. Bold letters represent amino acids that are
considered to be anchor residues. The candidate protein for the
individual ligand was assigned by database searching. For comparison,
the peptide motif of HLA-A2 is shown. Anchor residues are shown in
bold and preferred residues are underlined. Source: *histone H2A,
amino-acids 77–85; †‡unknown.
Figure 3
Peptide-binding assay: comparison of peptide binding between HLA-G
and HLA-A2.1. Cells were incubated overnight with peptide. MHC
class I surface expression was measured by FACS analysis, using
W6/32 as the primary antibody and synthetic peptides. (a)
LCL721.221 cells (black curve) and JY cells (light curve) were stained
to serve as negative and positive controls, respectively. (b,d,f,h)
LCL721.221 cells expressing HLA-G were incubated with the
following peptides: RIIPRHLQL (b), ILKEPVHGV (d), YMNGTMSQV
(f), or GRLTKHTKF (h). (c,e,g,i) LCL721.221 cells expressing HLA-
A2.1 were incubated with the peptides used in (b,d,f,h), respectively. In
(b–i), black curves denote incubations carried out in the absence of
peptide; light curves represent incubations in the presence of peptide.
— the combination of three restricted anchor residues
(isoleucine or leucine at position 2, proline at position 3
and leucine at position 9) and six more variable positions
— are comparable in stringency to those of classical MHC
molecules, implying that the peptide repertoire that is
presented has a similar diversity. In addition to the main
anchors, preferences for non-anchor residues are observed:
position 1 is preferentially positively charged and position
7 is hydrophobic in most ligands.
Although the carboxy-terminal anchor position could only
be detected in two of the pool sequencing experiments,
all individual peptide ligands had a leucine residue at the
carboxyl terminus. The failure to detect a carboxy-termi-
nal amino acid in some of the peptide pools is probably
technical, perhaps a result of inefficient fixation of pep-
tides in the sequencer. Peptide-binding studies further
confirmed that the amino acids at positions 2, 3 and 9 were
anchor residues. Substituting the residues at positions 2, 3
and 9 with glycine gradually diminished the stabilizing
effect of the HLA-G binding peptide KIPAQFYIL on
MHC class 1 density. Substitution of a single anchor
residue had virtually no effect in our binding assay,
whereas substitution of two anchors reduced the stabiliza-
tion effect by 50 %. Peptide KGGAQFYIG, in which
glycine replaces all three anchor positions, loses the MHC
I surface density stabilizing effect entirely. Glycine was
chosen for these substitution experiments because
alanine, which is commonly used for such purposes, might
have met the requirements (at least partially) for a
hydrophobic amino acid at anchor positions 2 and 9.
If the principles of the HLA-A2.1 structure [33,34] are
applied to HLA-G molecules, the peptide-binding pockets
of HLA-G can be predicted (Table 3) and the accommoda-
tion of the HLA-G ligand side chains in the binding groove
may be explained as follows. The amino-terminal residue
of the ligands is preferentially positively charged, probably
because of the negative character of the likely contact site
(formed by residues 5, 7, 59, 63, 66, 99, 159, 163, 167 and
171), which is negatively charged because of a glutamate
residue at position 63. The anchor at position 2 of HLA-G
ligands occupied by the aliphatic amino acids isoleucine or
leucine is likely to be accommodated by the B pocket
(formed by residues 7, 9, 24, 34, 45, 63, 66, 67, 70 and 99),
as in HLA-A2.1 [34]. The preference of HLA-G for
isoleucine side chains and of HLA-A2.1 for leucine is prob-
ably influenced by an amino-acid substitution at residue 9
of the HLA molecule. In HLA-G, the bulky phenylalanine
at position 9 is substituted by the smaller serine residue,
leading to a more spacious pocket which accommodates
isoleucine with a different configuration of the methyl
groups in the side chain. The proline residue at anchor
position 3 probably sets conformational constraints for the
peptide, which then fits more easily into the peptide-
binding groove of HLA-G. Hydrophobic residues at posi-
tion 7 are probably not accommodated in a specific pocket
either, but make contact with the HLA a2-helix [34].
Carboxy-terminal anchor side chains are accepted by the F
pocket (formed by residues 77, 80, 81, 84, 116, 123, 143,
146 and 147) in HLA-A2 molecules [34]. Pocket F in
HLA-A2.1 and in HLA-G differ only slightly at the pocket
rim. Therefore, leucine should be accepted by pocket F of
HLA-G, as in the case of the HLA-A2.1 F pocket [34].
HLA-G preferentially recognizes ligands containing a
leucine residue at position 9, whereas HLA-A2.1 prefers a
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Figure 4
Peptide-binding assay: analysis of the anchor residues of an HLA-G
binding peptide by glycine substitution. Cells were incubated overnight
with peptide. MHC class I surface expression was measured by FACS
analysis using W6/32 as the primary antibody. (a) LCL721.221 cells
expressing HLA-G, labelled with (light grey curve) and without (black
curve) primary antibody served as controls. The dark grey curve shows
the increase of MHC I surface expression upon incubation with the
peptide KIPAQFYIL. (b) Effect of substituting predicted anchor
residues on MHC class I surface stabilization. LCL721.221 cells
expressing HLA-G were incubated with KGGAQFYIG (left black
curve), KGGAQFYIL (right black curve) or KGPAQFYIL (grey curve).
valine residue at this position; this seems to correlate with
the downward orientation of the side chains at position 7 of
the ligand, and the substitution of arginine for tryptophan
at position 97 of HLA-G, which results in the amino-termi-
nal orientation of tyrosine at position 116 [34]. In addition,
some HLA-A2.1 ligands with carboxy-terminal valine
residues are able to bind to HLA-G in our peptide-binding
assay. In summary, the assumed HLA-G pocket structure
well reflects the ligand motif requirements.
Our peptide-binding assays confirm the sequence-
specificity of the HLA-G ligand motif, in that a HLA-B27
ligand and one of the HLA-A2.1 ligands do not bind. Fur-
thermore, the peptide-binding experiments indicate that
the binding requirements of HLA-G and HLA-A2.1
overlap. All individual HLA-G ligands have hydrophobic
amino acids in positions 2 and 9. It is therefore not surpris-
ing that they also bind to HLA-A2.1. Likewise, some of
the HLA-A2.1 ligands bind to HLA-G, exemplified by the
peptide ILKEPVHGV in our assay. On the other hand,
other HLA-A2.1 ligands do not bind to HLA-G, as repre-
sented by the peptide YMNGTMSQV. Thus, the partial
overlap in peptide-binding requirements for HLA-A2.1
and HLA-G emphasizes the fact that the general criteria
for peptide accommodation are shared between these
classical and nonclassical HLA molecules. 
HLA-G is an ortholog of the class I molecule of the New
World monkey, Saguinus oedipus, which diverged from the
human line 40 million years ago [22]. The HLA-G-related
class I molecules serve as classical restriction elements in
Saguinus oedipus [23]. The Saguinus oedipus class I mole-
cule is a peptide receptor with classical peptide-binding
specificities (B. Grahovac, K. Falk, G. Rötzschke, G. Jung,
S.S. and H-G.R., unpublished observations). We have
shown that the HLA-G motif is also classical; however, the
anchor positions and chemistry of the ligands are not con-
served between this and the Saguinus oedipus class I mole-
cule. This finding is not unexpected, because amino-acid
substitutions inside the peptide-binding pockets alter
their environment substantially.
HLA-G is a nonclassical MHC molecule. Other nonclassi-
cal MHC molecules with peptide-presenting functions
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Table 3
Comparison of the amino acids predicted to be contained within the peptide-binding pockets of HLA-G and HLA-A2.
(a) Predicted pockets contacting HLA-G ligands
Predicted contact-forming residues of the peptide ligands
(b) Predicted pockets which presumably do not interact with peptide ligands of HLA-G molecules
The relevant residues were identified on the basis of the HLA-A2.1 crystal structure [33]. Differences are highlighed in bold.
Pocket A
Position HLA-G HLA-A2
5 Met Met
7 Tyr Tyr
59 Tyr Tyr
63 Glu Glu
66 Asn Lys
99 Ile Tyr
159 Tyr Tyr
163 Thr Thr
167 Trp Trp
171 Tyr Tyr
Pocket B
Position HLA-G HLA-A2
7 Tyr Tyr
9 Ser Phe
24 Ala Ala
34 Val Val
45 Met Met
63 Glu Glu
66 Asn Lys
67 Thr Val
70 His His
99 Ile Tyr
Pocket F
Position HLA-G HLA-A2
77 Asn Asp
80 Thr Thr
81 Lys Lys
84 Tyr Tyr
116 Tyr Tyr
123 Tyr Tyr
143 Ser Thr
146 Lys Lys
147 Cys Trp
Pocket C
Position HLA-G HLA-A2
9 Ser Phe
70 His His
73 Thr Thr
74 Asp His
97 Trp Arg
Pocket D
Position HLA-G HLA-A2
99 Ile Tyr
114 Glu His
155 Gln Gln
156 Arg Leu
159 Tyr Tyr
160 Leu Leu
Pocket E
Position HLA-G HLA-A2
97 Trp Arg
114 Glu His
133 Trp Trp
147 Cys Trp
152 Val Val
156 Arg Leu
Pocket A
Position HLA-G HLA-A2
1 Arg, Lys –
Pocket B
Position HLA-G HLA-A2
2 Ile, Leu Leu, Met
Pocket F
Position HLA-G HLA-A2
9 Leu Val, Leu
have been described only in the mouse so far (reviewed in
[4]). The nonclassical mouse and human MHC molecules
are not homologous [1]. The mouse molecules function as
specialized peptide receptors — H2-M3 is especially
equipped to present N-formylated peptides [35,36], Qa-2
is specialized for histidine-containing peptides [37,38] and
Qa-1 preferentially presents signal sequences [39].
In comparison, nonclassical HLA-G molecules resemble
classical peptide receptors and the classical ortholog of
Saguinus oedipus, but not the nonclassical peptide recep-
tors of the mouse. In humans, however, no HLA-G-
restricted T lymphocytes have been reported yet [1].
Thus, we are left with the question as to what physiologi-
cal role HLA-G molecules may play. The ‘null hypothesis’
suggests that HLA-G has no function at all (reviewed in
[40,41]), but is an evolutionary relict. Another suggestion
is that HLA-G has a non-immunological function. Because
HLA-G molecules are selectively expressed on extra-
villous trophoblast, which invades uterine tissues during
the process of implantation, we have proposed that the
unusual CD56bright CD16– CD3– NK cells, which populate
the uterine mucosa at this time, control trophoblast inva-
sion by interacting with HLA-G [41,42]. We now find,
however, that HLA-G molecules present peptides, and
are very similar to classical HLA-A and HLA-B molecules.
It therefore seems likely that HLA-G has an immunologi-
cal function, as discussed below.
HLA-G molecules are selectively expressed at the
fetal–maternal interface. Because the fetus can be consid-
ered to be a semiallograft — it expresses paternal antigens
foreign to the mother’s immune system — there must be a
mechanism that prevents fetal rejection by the maternal
immune system. One obvious mechanism by which fetal
rejection can be prevented is by not expressing HLA-A
and HLA-B (and perhaps HLA-C) on the outer fetal
lining, the trophoblast. Thus, T cells alloreactive against
paternal HLA-A and HLA-B, as well as minor-histocom-
patibility-antigen-specific T cells, which recognize pater-
nal peptides presented by HLA-A or HLA-B molecules
that are shared between father and mother, can neither
recognize nor attack the intact fetus. Because HLA-G
itself exhibits limited polymorphism, it should not be a
target for alloreactivity by itself. However, the lack of
HLA-A, HLA-B, or HLA-C expression on a cell draws the
attention of another immune cell type, the NK cells.
NK cells are specialized to kill cells that no longer express
one or more of the HLA-A, HLA-B or HLA-C alleles
[43,44]. They perform this function by using two sets of
receptors, one of which is activating, the other inhibiting.
The activating NK receptors, which probably recognize
carbohydrate structures expressed on a wide array of target
cells, and the inhibitory receptors, which recognize
structures on HLA-B and HLA-C (and probably HLA-A)
molecules, are in a balanced state if either sees their
ligands. If the ligands if the inhibitory receptors are
missing, however, the target cell is killed [45]. This has
led to the formulation of the ‘missing-self’ hypothesis [46]. 
NK cells are found in great numbers in the decidua, a
tissue in intimate contact with the extravillous tro-
phoblast. NK cells freshly isolated from the decidua do
not kill trophoblast targets; they do so, however, after in
vitro culture with interleukin 2 [41,45]. Thus, trophoblast
cells have the potential to be lysed by NK cells, implying
that they express structures recognizable by activating NK
receptors. Because HLA-G is the only HLA molecule
shown to be expressed on trophoblast cells, it is likely that
this molecule serves as an NK inhibitor. Whether the pep-
tides presented by HLA-G are important for NK recogni-
tion, or merely act to stabilize the surface expression of
HLA-G, remains to be determined.
Thus, according to our hypothesis, the fetus protects itself
from being destroyed by alloreactive maternal T cells by
shielding itself with a layer of cells lacking HLA-A and
HLA-B expression. To avoid destruction of this layer by
NK cells, the trophoblast expresses the almost mono-
morphic HLA-G in order to stimulate every single one of
the inhibitory NK receptors, so that the balance is shifted
towards inhibition (Fig. 5).
In addition to inhibiting NK cells, peptide presentation by
HLA-G molecules could allow T cells to survey tro-
phoblast cells for viral infection or malignant transforma-
tion, as HLA-A, HLA-B or HLA-C restricted T cells do
with other cell types. This possibility had been discussed
by Schmidt and Orr [47] even before the peptide receptor
nature of HLA-G was discovered. A principal problem
here, however, is the obvious lack of HLA-G expression in
the thymus [41], which makes positive selection of HLA-
G restricted T cells an unlikely event. It remains to be
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Figure 5
A hypothesis for HLA-G function. Maternal cytotoxic T cells (CTLs)
directed against paternal HLA-A or HLA-B antigens cannot kill the
trophoblast because it lacks HLA-A and HLA-B. NK cells, which
usually recognize and kill cells that do not express HLA-A or HLA-B
molecules, are inhibited by HLA-G expression on trophoblast cells.
seen, therefore, whether HLA-G restricted T cells,
perhaps virus-specific, will be found in the future.
During preparation of this manuscript, Lee et al. [48]
reported an HLA-G peptide motif similar to ours, based
on ligand sequencing but without confirmation of the
anchor residues by binding assays.
Conclusions
HLA-G molecules are peptide receptors presenting pep-
tides derived from cellular proteins at the cell surface.
Like the classical HLA class I molecules, HLA-A, HLA-B
and HLA-C, HLA-G molecules present peptides with a
specific sequence motif, the basic features of which are
XI/LPXXXXXL. This information should be of great
value for determining the physiological function of
HLA-G molecules selectively expressed on the outermost
layer of the fetus, which is exposed immediately to mater-
nal blood and immune cells. Most likely, HLA-G mole-
cules function as inhibitors of NK cells, and thus avoid
destruction of the fetus by the maternal immune system.
In addition, peptide presentation by HLA-G expressed on
the trophoblast might allow T cell-mediated surveillance
of viral infection or malignant transformation, although
HLA-G restricted T cells have not yet been identified.
Materials and methods
Cell lines and antibodies
HLA-G transfectants [17] of the LCL721.221 HLA-null lymphoblastoid
cell line [27] were used as a source of HLA-G. HLA-A2.1 transfected
LCL721.221 cells [17], and untransfected parental cells served as
controls. Antibodies were affinity purified on protein A–Sepharose
beads by standard procedures from culture supernatants of the
hybridomas W6/32 (anti-HLA-class-I) [29] and BB7.2 (anti-HLA-
A2/A69) [49,50]. Transfectants were regularly analysed for transgene
expression by FACS analysis (data not shown).
Isolation of HLA-G molecules and ligands
HLA-G molecules and peptide ligands were isolated essentially as
described for HLA-A2 [30]. Cells were expanded at 37 °C in 2 l roller
bottles, containing Dulbeccos’s modified Eagle’s medium supplemented
with 25 mM Hepes, 2 mM glutamine, 5 % fetal calf serum, 5 % newborn
calf serum and 75 mg ml–1 hygromycin, to 1.5 × 106 cells per ml. In
some experiments, RPMI1640 medium containing 10 % FCS and sup-
plements was used. For each experiment, 1–4 × 1010 cells were lysed in
PBS, containing 1 % NP40 and protease inhibitors, for 1 h, while stir-
ring on ice. The lysate was precleared at 350 × g for 10 min and then
ultracentrifuged at 100 000 × g for 1 h. The cleared lysate was sterilized
by filtration and passed over immunoaffinity columns. After washing
away unbound material, ligands were eluted from the precipitated HLA
molecules by treatment with 0.1 % TFA at pH 2. TFA-extracted material
was subjected to ultrafiltration through Centricon 10 (Amicon) mem-
branes and the permeate was SpeedVac concentrated. The extracted
material of molecular weights below 10 kDa was separated by reversed-
phase HPLC (Pharmacia SMART system) on a narrow-bore HPLC-
column (2.1 mm, C2/C18; Pharmacia).
Peptide analysis
Pooled HPLC fractions [30] and individual fractions were sequenced
by Edman degradation on a protein sequencer (model 476A, Applied
Biosystems). Masses of individual fractions were determined by ESI- or
MALDI-MS on Finnigan TSQ 7000 and Finnigan Vision 2000 mass
spectrometers, respectively. Candidate protein sources were identified
by matching individual sequences in protein or nucleotide databases.
Peptide-binding assay with synthetic peptides
Synthetic peptides were synthesized by the Fmoc solid phase method
on a peptide synthesizer (model 432 A; Applied Biosystems). The pep-
tides were analyzed by reversed-phase HPLC and mass spectrometry.
We used three HLA-G binding peptides (RIIPRHLQL, RLPKDFRIL and
KLPAQFYIL), two HLA-A2 binding peptides (ILKEPVHGV and
YMNGTMSQV [3]), and one HLA-B27 binding peptide (GRLTKHTKF
[3]). In addition, the variant peptide KIPAQFYIL, and its glycine-substi-
tuted analogues, KGGAQFYIG, KGGAQFYIL and KGPAQFYIL, were
tested. The binding assays were performed with LCL721.221 cells
transfected with plasmids encoding HLA-G or HLA-A2.1. Untrans-
fected LCL721.22 cells served as a negative control, and JY cells were
used as a positive control. Cells (1 × 106) were pelleted for 10 min at
1 000 rpm, resuspended in 1 ml RPMI (containing 10 % FCS and sup-
plements), and incubated overnight for approximately 15 h with 200 mg
peptide at 37 °C in 24-well plates. FACS analysis was performed using
W6/32 as the primary antibody and a fluorescein isothiocyanate-
labelled goat anti-mouse antibody as the secondary antibody.
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